Microvesicle protein for cancer targeting

Abstract

Microvesicles play essential roles in disease progression. The present invention provides a novel microvesicle membrane protein and application thereof. Disclosed is method comprises phosphorylated CSE1L (cellular apoptosis susceptibility protein)- or CSE1L-binging agents for microvesicle isolation, analysis, or binding for disease diagnosis or treatment.

1 - 15 . (canceled) 
     
     
         16 . A pharmaceutical composition comprising an antibody against chromosome segregation 1-like protein (CSE1L) or an antibody against phosphorylated CSE1L and a pharmaceutical excipient, diluent or carrier. 
     
     
         17 - 20 . (canceled) 
     
     
         21 . The pharmaceutical composition of  claim 16 , wherein the antibody against phosphorylated CSE1L is an antibody that specifically recognizes phosphorylated CSE1L and does not recognize non-phosphorylated CSE1L or other phosphorylated proteins. 
     
     
         22 . The pharmaceutical composition of  claim 16 , wherein the carrier is a nanocrystal. 
     
     
         23 . A reagent composition comprising an antibody against CSE1L or an antibody against phosphorylated CSE1L for binding with tumor cells. 
     
     
         24 . The reagent composition of  claim 23 , wherein the antibody against phosphorylated CSE1L is an antibody that specifically recognizes phosphorylated CSE1L and does not recognize non-phosphorylated CSE1L or other phosphorylated proteins.